Patents Assigned to Oxford Biomedica (UK) Limited
  • Patent number: 10544429
    Abstract: The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 28, 2020
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Daniel Farley, Kyriacos Mitrophanous
  • Patent number: 10273502
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 30, 2019
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Patent number: 9738907
    Abstract: Provided is a multicistronic retroviral vector genome having a first nucleic acid sequence upstream of at least one internal regulatory element, such that the level of genomic RNA available for packaging in the absence of rev, or a functional equivalent thereof, is increased.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: August 22, 2017
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Philippa Radcliffe, James E. Miskin, Fraser J. Wilkes, Kyriacos A. Mitrophanous, Susan M. Kingsman
  • Publication number: 20170175135
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.
    Type: Application
    Filed: September 14, 2015
    Publication date: June 22, 2017
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Publication number: 20170073702
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 16, 2017
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Publication number: 20160231315
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 11, 2016
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventor: Richard Harrop
  • Patent number: 9339512
    Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: May 17, 2016
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Peter Widdowson, Scott Ralph, Kyriacos A. Mitrophanous
  • Patent number: 9169491
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilization step wherein the filter-sterilization step is not the final step in the purification process.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: October 27, 2015
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Publication number: 20130236479
    Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.
    Type: Application
    Filed: April 19, 2013
    Publication date: September 12, 2013
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Miles William Carroll, Abigail Lamikanra, Alan John Kingsman
  • Publication number: 20120213822
    Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 23, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
  • Publication number: 20120107862
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 3, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Peter Treasure
  • Patent number: 8147838
    Abstract: The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their used in diagnosis and therapy of cancer.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: April 3, 2012
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Richard Harrop, William Shingler, Susan Mary Kingsman
  • Patent number: 8133681
    Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: March 13, 2012
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
  • Publication number: 20120039943
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: January 8, 2010
    Publication date: February 16, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventor: Richard Harrop
  • Publication number: 20120027749
    Abstract: The present invention provides a method for detecting a 5T4-positive cancer in a subject, which comprises the following steps: (i) identifying and/or isolating exosomes in a sample from the subject; and (ii) detecting exosome-associated 5T4.
    Type: Application
    Filed: December 15, 2009
    Publication date: February 2, 2012
    Applicant: Oxford Biomedica (UK) Limited
    Inventor: Aled Clayton
  • Patent number: 8084249
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: December 27, 2011
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
  • Publication number: 20110269826
    Abstract: The present invention provides methods for: (i) treating and/or preventing Parkinson's disease in a subject without causing cognitive impairment by using dopamine replacement gene therapy to maintain or restore constant physiological dopaminergic tone in both the dorsal and ventral striatum of the subject; (ii) normalising neuronal electrical activity in basal ganglia and/or subthalamic nucleus in a Parkinson's disease subject; and (iii) treating and/or preventing dyskinesias associated with oral L-dopa administration in a Parkinson's disease subject by administration of a vector system for dopamine replacement gene therapy to the subject.
    Type: Application
    Filed: November 11, 2009
    Publication date: November 3, 2011
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Susan M. Kingsman, Alan J. Kingsman, Scott Ralph, Kyriacos A. Mitrophanous, Stephane Palfi, Bechir Jarraya
  • Publication number: 20110165668
    Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID NO: 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 4; (iv) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 5; (v) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 6; (vi) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.
    Type: Application
    Filed: January 3, 2011
    Publication date: July 7, 2011
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Miles Carroll, Susan Kingsman, Irina Redchenko
  • Publication number: 20110065173
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Application
    Filed: February 26, 2010
    Publication date: March 17, 2011
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
  • Publication number: 20110052577
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Application
    Filed: July 28, 2010
    Publication date: March 3, 2011
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers